SoFi stock falls after announcing $1.5B public offering of common stock
Investing.com -- Orion will receive a €180 million sales-based milestone payment from its partner Bayer for the drug Nubeqa during the fourth quarter of 2025, the company announced Wednesday.
The payment comes after some market uncertainty about whether it would be paid this year, especially since Orion had reduced its 2025 guidance in its third quarter results. Analysts had previously assumed the company would raise its outlook to include this milestone payment, which was already incorporated into consensus estimates.
As a result of the payment, Orion has updated its financial outlook for 2025. The company now expects net sales of €1,820-1,900 million, up from its previous guidance of €1,640-1,720 million. The current consensus estimate for net sales stands at €1,881 million.
Orion also revised its operating profit (EBIT) forecast to €590-670 million, increased from the previous range of €410-490 million. This compares to a consensus estimate of €644 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.